Clinical trial

Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis

NCT00367484

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2004-05-01

PhasePHASE4

Study timeline

Study start (unknown)2004-05-01Date precision: month

Registry last updated2014-02-27

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Relapsing Remitting Multiple Sclerosisunresolved

Interventions

Rebif® (clone 484-39)BIOLOGICAL

Sponsors & collaborators

Merck KGaA, Darmstadt, Germanylead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00367484 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.